News for Healthier Living

Immunotherapy Before and After Surgery Improves Outcomes in Head and Neck Cancer

Patients with locally advanced head and neck cancer who received the immune checkpoint inhibitor pembrolizumab before, during and after standard-of-care surgery had longer event-free survival without the cancer coming back and higher rates of substantial tumor shrinkage prior to surgery, according to the first interim analysis of a randomized, open-label phase 3 clinical trial led by investigators from Dana-Farber Brigham Cancer Center and Washington University School of Medicine in St. Louis.

April 27, 2025


April 27 2025

April 26 2025

April 25 2025

April 24 2025

April 23 2025

April 22 2025

April 21 2025

April 19 2025

April 18 2025

April 17 2025

April 16 2025

April 15 2025

April 14 2025